EU/U.S. strengthen oversight
This article was originally published in The Rose Sheet
Executive Summary
New confidentiality agreements between the European Commission and FDA will strengthen oversight of cosmetics by allowing the groups to exchange confidential safety information - such as advance drafts of legislation and/or regulatory guidance documents - as part of their regulatory mandate, EC announces July 5. Information also includes post-market data and reports on ongoing and emerging health and safety issues in the U.S. or EU. The agreement is in line with last week's launch of the Transatlantic Economic Council (TEC), designed to foster "closer economic cooperation" by harmonizing standards. "The EU and U.S. will be able to exchange early information to protect public health, whilst taking away stumbling blocks for trade," EC Vice President and European Chair of TEC Günter Verheugen notes. Regarding cosmetics, the agreement "represents an important step towards our goal of accepting each other's alternative methods to animal testing," Verheugen adds...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.